pd 173074 has been researched along with epidermal growth factor in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bosch-Barrera, J; Brunet, J; Cufí, S; de Llorens, R; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Queralt, B; Vazquez-Martin, A | 1 |
| Wakitani, S | 1 |
2 other study(ies) available for pd 173074 and epidermal growth factor
| Article | Year |
|---|---|
Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.
Topics: Amphiregulin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Survival; Cetuximab; Drug Resistance, Neoplasm; EGF Family of Proteins; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Gene Knockdown Techniques; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Ligands; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 3; Signal Transduction; Skin Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured | 2012 |
The FGF receptor inhibitor PD173074 modulates Lefty expression in human induced pluripotent stem cells differently depending on the culture conditions.
Topics: Epidermal Growth Factor; Humans; Induced Pluripotent Stem Cells; Left-Right Determination Factors; Pyrimidines; Receptors, Fibroblast Growth Factor | 2022 |